These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1132 related items for PubMed ID: 12581571

  • 21. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
    Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK, German and Swiss Lung Cancer Study Group.
    J Clin Oncol; 2004 Jun 15; 22(12):2348-56. PubMed ID: 15197195
    [Abstract] [Full Text] [Related]

  • 22. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
    Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M.
    J Clin Oncol; 1999 Nov 15; 17(11):3522-30. PubMed ID: 10550150
    [Abstract] [Full Text] [Related]

  • 23. Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).
    Grossi F, Belvedere O, Fasola G, Barbone F, Rizzato S, Sibau A, Recchia L, Vigevani E, Ceschia T, Morelli A, Guglielmi A, Puglisi F, Follador A, Talmassons G, Sobrero AF.
    Lung Cancer; 2004 Oct 15; 46(1):99-106. PubMed ID: 15364137
    [Abstract] [Full Text] [Related]

  • 24. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
    Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morère JF, Milleron B, Debieuvre D, Castéra D, Souquet PJ, Moro-Sibilot D, Lemarié E, Kessler R, Janicot H, Braun D, Spaeth D, Quantin X, Clary C.
    Ann Oncol; 2005 Apr 15; 16(4):602-10. PubMed ID: 15741225
    [Abstract] [Full Text] [Related]

  • 25. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.
    Chen YM, Perng RP, Chen MC, Tsai CM, Ming-Liu J, Whang-Peng J.
    Lung Cancer; 2003 May 15; 40(2):221-6. PubMed ID: 12711125
    [Abstract] [Full Text] [Related]

  • 26. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Souquet PJ, Fournel P, Bohas CH, Fortune IC, Chatte G.
    Semin Oncol; 1996 Apr 15; 23(2 Suppl 5):8-10. PubMed ID: 8610239
    [Abstract] [Full Text] [Related]

  • 27. Gemcitabine, vinorelbine, and Cisplatin in the treatment of advanced nonsmall cell lung cancer.
    Hasturk S, Hatabay N, Ece F, Karatasli M, Hanta I.
    Am J Clin Oncol; 2009 Jun 15; 32(3):280-5. PubMed ID: 19433960
    [Abstract] [Full Text] [Related]

  • 28. A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
    Blackhall FH, O'brien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ, Thatcher N.
    J Thorac Oncol; 2010 Aug 15; 5(8):1285-8. PubMed ID: 20661087
    [Abstract] [Full Text] [Related]

  • 29. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
    Kosmas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni N, Kourelis T, Malamos N, Antonopoulos M, Kalofonos HP.
    Eur J Cancer; 2001 May 15; 37(8):972-8. PubMed ID: 11334721
    [Abstract] [Full Text] [Related]

  • 30. Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: a phase II study.
    Recchia F, Lombardo M, De Filippis S, Rosselli M, Rea S.
    Anticancer Res; 2002 May 15; 22(2B):1321-8. PubMed ID: 12168945
    [Abstract] [Full Text] [Related]

  • 31. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS.
    Cancer; 2002 Jul 15; 95(2):340-53. PubMed ID: 12124835
    [Abstract] [Full Text] [Related]

  • 32. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D, Kalofonos HP, Samantas E, Nicolaides C, Papacostas P, Onyenadum A, Visvikis A, Skarlos D, Fountzilas G.
    Anticancer Res; 2001 Jul 15; 21(4B):3005-10. PubMed ID: 11712802
    [Abstract] [Full Text] [Related]

  • 33. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M, Villar Chamorro E, Alés Díaz I, Gil Calle S, Alcalde García J, Gutiérrez Calderón V, Carabantes Ocón F, Montesa Pino A, Bretón García JJ, Benavides Orgaz M.
    Clin Transl Oncol; 2006 Oct 15; 8(10):742-9. PubMed ID: 17074673
    [Abstract] [Full Text] [Related]

  • 34. Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).
    Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, Grossi F, Germano D, Matano E, Marini G, Labianca R, Di Costanzo F, Bagnulo A, Pennucci C, Caroti C, Mencoboni M, Zanelli F, Prochilo T, Cafferata MA, Ardizzoni A, Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
    Br J Cancer; 2012 Feb 14; 106(4):658-65. PubMed ID: 22240782
    [Abstract] [Full Text] [Related]

  • 35. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
    Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ, Lin CC, Huang TC, Yang PC, Yang CH.
    Lung Cancer; 2008 Dec 14; 62(3):334-43. PubMed ID: 18450322
    [Abstract] [Full Text] [Related]

  • 36. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial.
    Laack E, Mende T, Dürk H, Kneba M, Dickgreber N, Welte T, Müller T, Scholtze J, Graeven U, Jasiewicz Y, Edler L, Hossfeld DK.
    Eur J Cancer; 2002 Mar 14; 38(5):654-60. PubMed ID: 11916547
    [Abstract] [Full Text] [Related]

  • 37. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K, Japan Multi-National Trial Organisation.
    Lancet Oncol; 2008 Dec 14; 9(12):1135-42. PubMed ID: 19013107
    [Abstract] [Full Text] [Related]

  • 38. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
    Thomas P, Robinet G, Gouva S, Fournel P, Léna H, Le Caer H, Perol M, Berard H, Bombaron P, Vergnenegre A, Kleisbauer JP, Groupe français de pneumo-cancérologie.
    Lung Cancer; 2006 Jan 14; 51(1):105-14. PubMed ID: 16310886
    [Abstract] [Full Text] [Related]

  • 39. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
    Han JY, Lee DH, Song JE, Lee SY, Kim HY, Kim HT, Lee JS.
    Cancer; 2008 Jul 15; 113(2):388-95. PubMed ID: 18484595
    [Abstract] [Full Text] [Related]

  • 40. Interim analysis of a phase III trial. Triple- vs double-agent chemotherapy for advanced non-small-cell lung cancer. Southern Italy Cooperative Oncology Group.
    Comella P.
    Oncology (Williston Park); 2000 Jul 15; 14(7 Suppl 4):35-40. PubMed ID: 10960944
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.